Analysts' Top 5 Price Targets of May 20, 2025
Reading Time: 3 minutes
Eton Pharmaceuticals [US29772L1089]: H.C. Wainwright reiterates the Buy rating with a price target of $33 (120% upside potential) After the investor day and the fourth-quarter results, H.C. Wainwright maintains its buy recommendation. Fourth-quarter revenue was $11.6 million, exceeding Wall Street expectations of $10.5 million. Additionally, management provided guidance for 2025, aiming for an annual revenue of $80 million. In the near future, it plans to surpass the $100 million mark, driven by acquisitions, the growth of Alkindi, and the launch...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
